BioNexus Gene Lab Profit Margin

The latest profit margin for BGLC is -54.7% as of March 2026. That compares with -22.86% in the prior-year period — down 139.3% year over year. That is below the sector sector average of 19.61%. Investors often review this figure alongside BioNexus Gene Lab's historical trend and sector peers before judging valuation or financial health.

Over the past year, BGLC's profit margin moved from -22.86% to -54.7% — a 139.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioNexus Gene Lab's valuation or profitability profile.

Against its sector companies, BGLC currently prints -54.7% for profit margin, while the sector average sits near 19.61%. That is roughly 379.0% below the sector mean. Large gaps often invite a closer look at BioNexus Gene Lab's growth, margins, and balance sheet.

Profit Margin shows how effectively BioNexus Gene Lab converts resources into returns. At -54.7%, BGLC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -22.86% in the prior-year period — down 139.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BGLC's profit margin (-54.7%), review year-over-year change from -22.86%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.